Molecules, 2022 Lung adenocarcinoma (LADC) is the most prevalent lung cancer sub-type, and targeted therapy developed in recent years has made progress in its treatment.
Xue Zhu, Ke Wang, Xiyue Li
exaly +4 more sources
Frontiers in Pharmacology, 2021 Objective: A robust, quick, and reliable ultra-performance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for the quantification of erdafitinib in beagle dog plasma was developed and validated to evaluate the changes of posaconazole ...
Xiang-Jun Qiu
exaly +3 more sources
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
Frontiers in Oncology, 2020 ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR.
Dong-Hua Yang, Weiguo Feng, Qingbin Cui
exaly +3 more sources
Frontiers in Pharmacology, 2023 Purpose: On 12 April 2019, erdafitinib gained the first FDA approval as the second-line treatment for adult patients with locally advanced or metastatic urothelial cancer following progression during or after at least one previous line of platinum-based ...
Yuchuan Hou
exaly +3 more sources
pH-responsive acetylated PAMAM dendrimer nanocarriers for enhanced intravesical delivery of Erdafitinib in urothelial carcinoma [PDF]
Scientific ReportsUrothelial carcinoma, the most frequent type of bladder cancer, is associated with high recurrence and low efficacy of standard treatments. Erdafitinib, an FGFR inhibitor, has therapeutic potential but is limited by systemic toxicity, poor tumor ...
Gowdru Vishwanath Nahusha +9 more
doaj +2 more sources
Erdafitinib suppresses pathological retinal angiogenesis via dual targeting of FGFR and VEGFR2 signaling [PDF]
Scientific ReportsPathological retinal angiogenesis drives vision loss in diseases like proliferative diabetic retinopathy (PDR) and retinal vein occlusion (RVO). Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor, has shown therapeutic potential in ...
Yingli Mo +7 more
doaj +2 more sources
Design and synthesis of an erdafitinib-based selective FGFR2 degrader [PDF]
Beilstein Journal of Organic ChemistryThis study aimed to develop a novel degrader capable of selectively degrading fibroblast growth factor receptor 2 (FGFR2) to overcome the issues of drug resistance and adverse reactions associated with traditional inhibitors in the treatment of FGFR2 ...
Yumeng Jin +7 more
doaj +2 more sources
MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells [PDF]
Cell Death and DiseaseMuscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high recurrence and poor survival, accounting for the majority of bladder cancer–related deaths.
Syunta Makabe +12 more
doaj +2 more sources
Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer [PDF]
Nature CommunicationsFibroblast growth factor receptor (FGFR) alterations are targetable in metastatic urothelial carcinoma (mUC). Identifying FGFR alterations currently requires tissue testing, which is limited by sample availability and cancer heterogeneity.
David C. Müller +42 more
doaj +2 more sources
Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4 [PDF]
Breast Cancer ResearchTriple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC), characterized by limited treatment options and poor clinical outcomes.
Qing Luo +13 more
doaj +2 more sources